Search clinical trials for: DZD9008 AZD4205

Total 66 results

Dizal Pharmaceuticals

Recruiting

A Phase II Clinical Trial of DZD9008 in Combination With AZD4205 in Standard Treatment Failed NSCLC Patients With EGFR Mutations (WU-KONG21)

Non-small Cell Lung Cancer

China
Dizal (Jiangsu) Pharmaceutical Co., Ltd.
PPD Development, L.P.

Recruiting

DZD9008 PK Study in Hepatic Impairment Subjects

Hepatic Impairment

United States
Peking Union Medical College Hospital
Dizal (Jiangsu) Pharmaceutical Co., Ltd.

Recruiting

Assessing an Oral EGFR Inhibitor, DZD9008 in Patients With Advanced Non-small Cell Lung Cancer(NSCLC) With EGFR Mutations (WU-KONG15) (WU-KONG15)

Non Small Cell Lung Cancer

China
Dizal Pharmaceuticals

Completed

Pharmacokinetic and Mass Balance Study of Oral-Administrated [14C]-DZD9008 in Healthy Male Subjects

Healthy Volunteers

United States
Dizal Pharmaceuticals

Active, not recruiting

DZD9008 in Pretreated Lung Cancer Patients With EGFR Exon20 Insertion Mutation

Non-Small Cell Lung Cancer

China
Dizal Pharmaceuticals

Completed

Assessing the Safety, Tolerability and Pharmacokinetics(PK) of DZD9008 and the Effect of Low-fat Meal on PK of DZD9008 in Healthy Adult Participants

Healthy Volunteers

United States
Dizal Pharmaceuticals

Active, not recruiting

Assessing an Oral EGFR Inhibitor, Sunvozertinib in Patients Who Have Advanced Non-small Cell Lung Cancer With EGFR or HER2 Mutation (WU-KONG1)

Non-Small Cell Lung Cancer

Korea, Republic of, Spain, United States, France, Taiwan, Italy, China, Argentina, Australia, Malaysia, Canada, Japan, Chile
Dizal Pharmaceuticals

Completed

A Study of AZD4205 in Healthy Adult Subjects (JACKPOT2)

Healthy Volunteers

United States
Dizal Pharmaceuticals

Completed

Assessing An Oral Janus Kinase Inhibitor, AZD4205 as Monotherapy in Patients Who Have PTCL (JACKPOT8)

Relapsed or Refractory Peripheral T Cell Lymphoma

Korea, Republic of, United States, China, Australia
Dizal Pharmaceuticals

Completed

Assessing an Oral Janus Kinase Inhibitor, AZD4205, in Combination With Osimertinib in Patients Who Have Advanced Non-small Cell Lung Cancer (JACKPOT1)

Nonsmall Cell Lung Cancer

Australia
Dizal Pharmaceuticals

Suspended

Assessing an Oral Bruton Tyrosine Kinase Inhibitor, DZD9008 in Patients Who Have Non-Hodgkin B-cell Lymphoma (WU-KONG3)

Non-Hodgkin's B-cell Lymphoma

China
AstraZeneca

Not yet recruiting

A Randomised, Double-blind, Parallel Group, Placebo Controlled, 4-Week, Phase II Study to Evaluate the Effect of AZD4604 on Airway Inflammation and Biomarkers in Adults With Asthma (ARTEMISIA)

Asthma

Canada, Denmark, Germany, Spain, United Kingdom
AstraZeneca

Recruiting

First in Human Study to Evaluate AZD8205 in Patients With Advanced or Metastatic Solid Malignancies

Breast Cancer | Ovarian Cancer | Endometrial Cancer | Biliary Tract Carcinoma

United States, Spain, Australia, United Kingdom, Korea, Republic of, Belgium, Canada, China, Japan, Taiwan, Thailand, Hungary, Poland, Netherlands
AstraZeneca

Recruiting

AZD0305 as Monotherapy or in Combination With Anticancer Agents in Participants With Relapsed/Refractory Multiple Myeloma

Multiple Myeloma

United States, Spain, Australia, Canada, France, China, Japan, Germany
AstraZeneca

Completed

Global Phase1 Study to Assess the Safety and Tolerability of AZD1208 in Advanced Solid Tumors and Malignant Lymphoma

Advanced Solid Malignancies | Malignant Lymphoma

United Kingdom, Japan
AstraZeneca

Terminated

Safety, Tolerability, Pharmacokinetics and Efficacy of AZD1208 in Acute Myelogenous Leukemia (AML) Patients

Acute Myeloid Leukemia

United States, Canada
AstraZeneca

Completed

Cardiac Electrophysiological Study

Atrial Flutter

Finland, Norway, Denmark, Sweden
AstraZeneca

Completed

Study to Assess Drug Concentrations in Plasma of Different Extended-release Formulations of AZD1305

Healthy

United Kingdom
AstraZeneca

Completed

A Phase I Study of AZD4635 in Japanese Patients With Advanced Solid Malignancies

Advanced Solid Malignancies

Japan
AstraZeneca

Completed

Evaluate Different Extended-release (ER) Tablets/Capsules of AZD1305 (2007-005765-38)

Healthy

United Kingdom
AstraZeneca

Completed

Phase I Dose-Escalation Study of AZD4785 in Patients With Advanced Solid Tumours

Non-Small Cell Lung Cancer | Advanced Solid Tumours

United States, United Kingdom
AstraZeneca

Terminated

AZD1305 Single and Multiple Ascending Dose Study in Healthy Japanese and Caucasian Subjects (JMAD)

Healthy

United States
Arrow Therapeutics

Completed

Clinical Pharmacology Study of AZD7295 in Healthy Subjects

Healthy

United Kingdom
AstraZeneca

Completed

A Study of AZD4901 in Females With Polycystic Ovary Syndrome

Polycystic Ovary Syndrome (PCOS), Female Endocrine Disorder

United States, United Kingdom, Germany
AstraZeneca

Completed

A Clinical Trial in Healthy Volunteers and Patients With Mild Asthma to Investigate a New Medicine (AZD4604) for the Treatment of Asthma

Asthma

United Kingdom
AstraZeneca

Completed

Intravenous Cardioversion of Atrial Fibrillation (AF) With AZD1305

Atrial Fibrillation

Sweden, Czech Republic, Hungary, Poland, Netherlands, Norway, Denmark, Slovakia
AstraZeneca

Completed

Explorative Study of AZD1305 in Atrial Fibrillation Patients

Atrial Fibrillation

Russian Federation, Poland, Denmark, Norway, Slovakia, Sweden
AstraZeneca

Completed

Study of an Extended Release (ER) Tablet, Single and Repeated Dosing

Healthy

Sweden
Arrow Therapeutics

Completed

Pharmacokinetics of AZD7295 Capsules

Healthy

United Kingdom
AstraZeneca
Quotient Sciences

Completed

AZD4635 Relative Bioavailability Study (Rel Bio)

Healthy Volunteers

United Kingdom
Dizal Pharmaceuticals

Completed

Pharmacokinetic and Mass Balance Study of Orally Administered [14C]-AZD4205 in Healthy Adult Male Volunteers

Healthy Volunteers

United States
AstraZeneca
Quotient Sciences

Completed

An ADME Study of [14C]AZD4604 and the Absolute Bioavailability of AZD4604

Asthma

United Kingdom
Acacia Pharma Ltd

Completed

Dose-ranging Study of APD405 in Post-operative Nausea and Vomiting (PONV)

Postoperative Nausea and Vomiting

United States, Switzerland, Germany, France
AstraZeneca

Recruiting

Phase 2a Study to Assess the Efficacy and Safety of AZD4604 in Adult Patients With Moderate-to-Severe Asthma Uncontrolled on Medium-High Dose ICS-LABA (AJAX)

Asthma

Denmark, United States, South Africa, United Kingdom, Argentina, Vietnam, Brazil, Malaysia, Taiwan, France, Germany, Spain, Thailand, Bulgaria, Philippines, Sweden
AstraZeneca

Completed

To Study the Absorption, Distribution, Metabolism and Excretion of AZD1305

Healthy

United Kingdom
AstraZeneca

Completed

To Study Safety, Tolerability and Pharmacokinetics of AZD1305 in Healthy Male Japanese Subjects

Healthy

Japan
AstraZeneca

Recruiting

Phase I/IIa Study for AZD5335 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Solid Tumors (FONTANA)

Ovarian Cancer | Lung Adenocarcinoma

United States, China, Spain, Canada, Australia, Taiwan, Israel, Japan, United Kingdom
AstraZeneca

Completed

Single Ascending Dose Study (SAD) iv Formulation (2006-006253-27)

Healthy

Sweden
AstraZeneca

Completed

Study to Investigate Safety, Tolerability and PK Following Single and Multiple Ascending Doses of AZD7295 in Japanese

Healthy Subjects

Japan
AstraZeneca
Parexel

Recruiting

A Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD1705 in Participants With Dyslipidemia

Cardiovascular

United States
AstraZeneca

Completed

Investigate the Effect of AZD1305 on Patients With Left Ventricular Dysfunction

Left Ventricle Function

Sweden
AstraZeneca
Parexel

Not yet recruiting

A Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD1705 in Participants With Dyslipidemia

Cardiovascular

United States
Arrow Therapeutics

Completed

Antiviral Activity of AZD7295 in HCV Carriers

Hepatitis C

New Zealand
Imperial College London
AstraZeneca; Medical Research Council; National Institute for Health Research...

Completed

Neuropeptide Treatment for Hot Flushes During the Menopause (NK3R)

Menopausal Flushing

United Kingdom
AstraZeneca

Recruiting

A Study to Investigate the Biological Effects of Saruparib (AZD5305), Darolutamide, and in Combination in Men With Newly Diagnosed Prostate Cancer. (ASCERTAIN)

Prostate Cancer

United States, Spain, United Kingdom, Netherlands, Canada, Australia
Dizal Pharmaceuticals

Recruiting

A Study of DZD9008 Versus Platinum-Based Doublet Chemotherapy in Local Advanced or Metastatic Non-small Cell Lung Cancer (WU-KONG28)

Non-small Cell Lung Cancer

China, United States, Argentina, Australia, Austria, Belgium, Brazil, Canada, Czechia, France, Germany, Italy, Netherlands, Poland, Spain, Turkey
Dizal Pharmaceuticals

Recruiting

DZD9008 In Combination With Bevacizumab in Locally Advanced or Metastatic NSCLC Patients With EGFR Mutation (WU-KONG29)

Non-small Cell Lung Cancer

China
Dizal Pharmaceuticals

Completed

Drug-drug Interactions Between DZD9008 and Itraconazole/Carbamazepine

Healthy Subjects

United States
Henan Cancer Hospital

Recruiting

Go-CHOP as the Frontline Therapy for PTCL

Peripheral T Cell Lymphoma

China
AstraZeneca
Parexel

Completed

A Study of AZD4635 With Durvalumab and With Cabazitaxel and Durvalumab in Patients With mCRPC. (AARDVARC)

Progressive Metastatic Castrate-Resistant Prostate Cancer

United States, Spain, Belgium, France, Korea, Republic of

3

Subscribe